Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Extremecare
- Development stage
- Phase 2
- Lead developer
- Instituto Brasileiro de Controle do Câncer
- Administration
- Topical
01
Overview
**Extremecare** is a topical moisturizing cream developed for skin care in oncology patients, including prevention of capecitabine-associated hand-foot syndrome. Its formulation contains multiple moisturizing, emollient, botanical, and antioxidant components, including glycerin, hazelnut oil, calendula oil, shea butter, chamomile, oat extract, Aloe vera, vitamin E, and Thoitaine. It does not have a defined receptor-mediated pharmacologic mechanism; its intended action is to support skin-barrier hydration, reduce dryness and desquamation, and improve comfort in treatment-affected skin. Extremecare was evaluated in the Phase 2 randomized, placebo-controlled TACX Care trial in patients receiving capecitabine.
- Brand names
- Extremecare
Beyond the preview
Go deeper on Extremecare.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Extremecare.